Related Experiment Video
Updated: Aug 5, 2026

A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
Bleeding Events During Anticoagulation After Acute Pulmonary Embolism: Real-Life Experience
Irina Pocienė1,2, Brigita Lebednykienė1, Jolita Račkauskienė1
1Centre of Pulmonology and Allergology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania.
Anticoagulant therapy for pulmonary embolism (PE) can cause bleeding, mostly minor. Prolonged treatment is safe if indicated, but ongoing bleeding risk assessment is crucial for patients with PE.
Area of Science:
- Cardiology
- Pulmonology
- Hematology
Background:
- Pulmonary embolism (PE) is a serious condition requiring anticoagulant therapy.
- Anticoagulants reduce recurrent PE but increase bleeding risk.
- Optimal anticoagulant duration for PE is challenging due to balancing risks.
Purpose of the Study:
- To evaluate bleeding rates during anticoagulant therapy post-PE.
- To identify risk factors for bleeding complications.
Main Methods:
- Prospective study of 201 patients with acute PE.
- Recording and classifying bleeding events (major/minor) during follow-up.
- Analyzing potential risk factors for bleeding.
Main Results:
- 17.4% of patients experienced bleeding (2.5% major, 14.9% minor).
- Extended anticoagulation (>6 months) showed more non-major bleeding events.
- Prior bleeding, unprovoked PE, elevated BNP, and high early mortality risk were associated with increased bleeding.
Conclusions:
- Bleeding after PE treatment is common but usually minor.
- Prolonged anticoagulation appears safe when clinically justified.
- Regular reassessment of bleeding risk is essential for PE patients.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care